Stallergènes Snapshot
Stallergènes is focused on the development, manufacture, and distribution of immunotherapeutic treatments for food-related and environmental allergies. The company has brought together experts in the fields of biology, botany, and the health community to collaborate on finding ways to deliver relief to people who suffer with problems such as asthma and seasonal allergies. These immunotherapy treatments involve conditioning the patient with drugs that introduce pure extracts of the allergen to initiate the body's own natural defenses against it. Ares Life Sciences owns about a 70% stake in the company. Stallergènes has research laboratories in Africa, the Americas, Asia, Australia, Europe, and the Middle East.